Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fi...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2020]
|
| In: |
Respiratory research
Year: 2020, Jahrgang: 21 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-019-1269-6 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-019-1269-6 |
| Verfasserangaben: | Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693475723 | ||
| 003 | DE-627 | ||
| 005 | 20230427033652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200330s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-019-1269-6 |2 doi | |
| 035 | |a (DE-627)1693475723 | ||
| 035 | |a (DE-599)KXP1693475723 | ||
| 035 | |a (OCoLC)1341311424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Valenzuela, Claudia |e VerfasserIn |0 (DE-588)1207283738 |0 (DE-627)1693476932 |4 aut | |
| 245 | 1 | 0 | |a Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |c Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter |
| 264 | 1 | |c [2020] | |
| 300 | |b Illustrationen | ||
| 300 | |a 151 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.03.2020 | ||
| 520 | |a The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases. | ||
| 700 | 1 | |a Torrisi, Sebastiano Emanuele |e VerfasserIn |0 (DE-588)1190667231 |0 (DE-627)1669225615 |4 aut | |
| 700 | 1 | |a Kahn, Nicolas |d 1982- |e VerfasserIn |0 (DE-588)1023650371 |0 (DE-627)718423941 |0 (DE-576)367217635 |4 aut | |
| 700 | 1 | |a Quaresma, Manuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stowasser, Susanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d London : BioMed Central, 2001 |g 21(2020) Artikel-Nummer 7, 15 Seiten |h Online-Ressource |w (DE-627)326646485 |w (DE-600)2041675-1 |w (DE-576)107014823 |x 1465-993X |7 nnas |a Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g extent:151 |a Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12931-019-1269-6 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200330 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 6 |y j | ||
| 998 | |g 1023650371 |a Kahn, Nicolas |m 1023650371:Kahn, Nicolas |d 910000 |d 950000 |d 950900 |e 910000PK1023650371 |e 950000PK1023650371 |e 950900PK1023650371 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 3 | ||
| 999 | |a KXP-PPN1693475723 |e 3615654684 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1693475723","note":["Gesehen am 30.03.2020"],"language":["eng"],"person":[{"given":"Claudia","roleDisplay":"VerfasserIn","role":"aut","display":"Valenzuela, Claudia","family":"Valenzuela"},{"family":"Torrisi","display":"Torrisi, Sebastiano Emanuele","role":"aut","roleDisplay":"VerfasserIn","given":"Sebastiano Emanuele"},{"display":"Kahn, Nicolas","given":"Nicolas","role":"aut","roleDisplay":"VerfasserIn","family":"Kahn"},{"given":"Manuel","roleDisplay":"VerfasserIn","role":"aut","display":"Quaresma, Manuel","family":"Quaresma"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Susanne","display":"Stowasser, Susanne","family":"Stowasser"},{"given":"Michael","role":"aut","roleDisplay":"VerfasserIn","display":"Kreuter, Michael","family":"Kreuter"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"BioMed Central","dateIssuedDisp":"2001-","publisherPlace":"London","dateIssuedKey":"2001"}],"disp":"Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programmeRespiratory research","language":["eng"],"title":[{"title_sort":"Respiratory research","title":"Respiratory research"}],"id":{"issn":["1465-993X"],"zdb":["2041675-1"],"eki":["326646485"]},"pubHistory":["1.2000 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 04.08.22"],"recId":"326646485","part":{"text":"21(2020) Artikel-Nummer 7, 15 Seiten","year":"2020","extent":"151","volume":"21"}}],"name":{"displayForm":["Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter"]},"id":{"eki":["1693475723"],"doi":["10.1186/s12931-019-1269-6"]},"physDesc":[{"noteIll":"Illustrationen","extent":"151 S."}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[2020]"}],"title":[{"title_sort":"Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme","title":"Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme"}]} | ||
| SRT | |a VALENZUELAONGOINGCHA2020 | ||